Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading Risk Factors below, as well as those discussed elsewhere in this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors th…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
▼ -70.0% YoY
Net Income (TTM)
-$67M
▲ +20.8% YoY
Op. Margin
-132871.32%
▼ -81254.4pp YoY
ROIC
-354.67%
▼ -36.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$81M
▲ +15.0% YoY
Op. Cash Flow (TTM)
-$81M
▲ +14.8% YoY
Net Debt
-$29M
Net Cash Position
Cash & Equiv.
$37M
5Y CAGR: -61.2%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with INO
Held by ETFs
INO is in 1 US ETF. The largest of them, with INO's weight in each:
Inovio Pharmaceuticals (INO) in three numbers
Questions about Inovio Pharmaceuticals
Is Inovio Pharmaceuticals a high-quality business?
Inovio Pharmaceuticals scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$29M, and its weakest is return on capital at -354.7%. The Quality tab shows every check against its target.
Does Inovio Pharmaceuticals (INO) pay a dividend?
No. Inovio Pharmaceuticals (INO) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in INO's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing INO
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.